LifeMD ($LFMD) Misrepresentation of Growth, Rising Costs, and Insider Sales Case
$LFMD investors filed a claim against LifeMD for overstating its growth trajectory, misrepresenting the strength of its RexMD and GLP-1 businesses, and issuing unrealistic financial guidance.
After lowering full-year guidance on August 5, 2025, citing acquisition cost issues and patient refund rates, $LFMD collapsed 44.8%.
$LFMD investors can join this case to be notified about potential recovery.
Case Details:
Between May 7, 2025, and August 5, 2025, LifeMD executives repeatedly told investors that demand across its telehealth platform was accelerating, RexMD was performing strongly, and partnerships with NovoCare and LillyDirect gave it a competitive advantage in the GLP-1 weight management market. The company also raised its full-year 2025 revenue guidance to $268–$275 million and adjusted EBITDA to $31–$33 million.
In reality, LifeMD’s customer acquisition costs in RexMD and weight management were climbing sharply, refund rates were rising, and growth assumptions were unsustainable. Executives knew or recklessly disregarded that the raised guidance could not be achieved. Insiders, including the CEO, sold millions in stock before the truth came out.
The truth emerged on August 5, 2025, when LifeMD cut its revenue guidance to $250–$255 million and adjusted EBITDA to $27–$29 million, citing “temporary challenges” in RexMD and higher refund rates in GLP-1 programs. The next day, $LFMD crashed 44.8%.
Based on these events, $LFMD investors filed a claim against LifeMD, alleging the company:
It misrepresented the performance and sustainability of RexMD and GLP-1 programs.
It concealed rising customer acquisition costs and refund rates.
It artificially inflated its stock price through reckless guidance and misleading statements.
Investors argue LifeMD misled the market about its financial health and business trajectory while insiders profited from stock sales.